Andrew Cheng, President and CEO at Akero Therapeutics, Inc. (AKRO), sold 30,000 shares at $53.98 ($1.6M) on 2025-10-10, disclosed to the SEC on 2025-10-14.
Scheduled sale ($1.6M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-07-11 | $3.1M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $726K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $4.1M | — | Filing → |